There is so much upside which will occur in the next few months,...

There is so much upside which will occur in the next few months, and the drug has already gone through the FDA review, the only review needed is on the packaging and user manual. The risk during Phase 3 trials is that the drug will not be approved, in BOT's case it is a review of the packaging, one would think this is a far lesser risk for approval. I believe along with I would say most people, that BOT's drug will be approved come June, and in the lead up to this date BOT will become more visible to people as they start to study the company due to the timeframes to approval. This demand will far outstrip the current supply and the share price will increase.

There are those on the ASX who do not follow the FDA trial dates to search for potential companies to invest in, but may see and follow companies who have large volumes traded and large increases in share price. BOT will have both of those, and then BOT will gain yet more attention.

And then once BOT is approved by FDA come June, and even more-so when sales start to occur in the US, BOT will not be trading in single digit dollar figures in the following years.

All the best to all holders, BOT is such a low market capped share price compared to the minimal risk, and the upside potential is larger than some investors realise.